{
  "id": 5656345,
  "title": "Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided?",
  "url": "https://urgent.news/2026/09/03/is-johnson-johnson-stock-priced-for-more-growth-than-it-has-guided",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-03T15:24:52.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/markets/stocks/articles/johnson-johnson-stock-priced-more-152452922.html"
  },
  "original_language": "en",
  "account": "Johnson & Johnson (JNJ) has experienced a significant increase in stock value over the past year, rising 56.5% compared to the S&P 500's 19.1% growth. Currently trading at $271.19, the stock is near its 52-week high and commands a modest earnings multiple of 6.7, which aligns with JNJ's historical performance. However, analysts argue that the current valuation may be overly reliant on faster-than-expected top-line growth. Based on our valuation model, achieving a 12% annual revenue growth over the next three years—required to justify today's price—appears unlikely, given that JNJ's quarterly sales growth is projected at 7.0% to 7.6% for 2026.\n\nWhile JNJ reported $97.9 billion in revenue in the last year, up 8.1% year-over-year, this figure falls short of the 11.9% annual growth rate presumed to meet the stock's valuation expectations. The 2026 earnings target of double-digit growth remains a challenge, particularly without substantial contributions from new medicines such as TREMFYA and DARZALEX. On the other hand, MedTech generated $8.9 billion in the second quarter, with a modest 3.6% growth rate, highlighting the slower performance of JNJ's other segments.\n\nManagement acknowledges cardiovascular results as a concern, and the company's PROTECT IV trial, anticipated in 2027, may provide some relief. Yet, the options market has already priced in potentially larger-than-normal moves, implying volatility at 22%, which is higher than its historical average. For concentrated investors, this scenario could pose significant risks, as highlighted by our proprietary analysis.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}